Inactive Instrument

Radius Health, Inc.

Equities

RDUS

US7504692077

Biotechnology & Medical Research

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
EffRx Pharmaceuticals Signs Exclusive Licensing and Distribution Agreement with Radius Health, Inc for Binosto for the United States CI
Radius Health, Inc. Announces the Appointment of Al Medwar as Senior Vice President and Corporate Development CI
Radius Health, Inc. Appoints Erika Tooman as Senior Vice President/ General Counsel CI
Theramex Enters into an Exclusive Licensing Agreement with Radius Health Inc, to Commercialise ELADYNOS in the European Economic Area, United Kingdom, Australia and Brazil CI
Radius Health, Inc. announced that it has received funding from Webster Equity Partners, LLC CI
Radius Health's Tymlos® (Abaloparatide) Receives U.S. FDA Approval as A Treatment to Increase Bone Density in Men with Osteoporosis At High Risk for Fracture CI
Ambrx Biopharma Names Kate Hermans Interim CEO MT
Radius Health, Inc. Announces Board Changes CI
Radius Health, Inc. Enters into Credit Agreement CI
Radius Health, Inc.(NasdaqGM:RDUS) dropped from NASDAQ Composite Index CI
Radius Health, Inc.(NasdaqGM:RDUS) dropped from S&P TMI Index CI
Radius Health, Inc.(NasdaqGM:RDUS) dropped from S&P Global BMI Index CI
Radius Health, Inc.(NasdaqGM:RDUS) dropped from S&P Biotechnology Select Industry Index CI
Radius Health, Inc.(NasdaqGM:RDUS) dropped from NASDAQ Biotechnology Index CI
Patient Square Capital, LP and Gurnet Point Capital Limited completed the acquisition of Radius Health, Inc. from Repertoire Partners LP, Velan Capital Investment Management LP and others. CI
Radius Health, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
Radius Health, Inc. and Teijin Pharma Limited Enter into an Amendment to License and Development Agreement CI
Velan-Repertoire to Withdraw Director Nominations due to Pending Sale of Radius Health CI
Radius Health Inc Issues an Investor Presentation to Shareholders CI
Radius Health Solicits Proxies from Shareholders CI
Radius Health Says First Patient Randomized in Trial of Prader-Willi Syndrome Symptoms MT
Radius Health, Inc. Announces First Patient Randomized in the Rad011 Pivotal Trial for Prader-Willi Syndrome CI
Radius Health, Inc Provides Information to the Shareholders CI
Velan Capital Investment Comments on Proposed Sale of Radius Health to Gurnet Point Capital and Patient Square Capital CI
SVB Securities Adjusts Radius Health's Price Target to $10 from $7, Keeps Market Perform Rating MT
Chart Radius Health, Inc.
More charts
Radius Health, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing endocrine therapeutics. Its lead product, TYMLOS (abaloparatide) injection, is a prescription medicine for the treatment of postmenopausal women with osteoporosis at high risk for fracture. The Company also has products in clinical pipeline, which includes investigational abaloparatide injection for potential use in the treatment of men with osteoporosis; an investigational abaloparatide patch for potential use in the treatment of postmenopausal women with osteoporosis; the investigational drug, elacestrant (RAD1901), for potential use in the treatment of hormone-receptor positive breast cancer out-licensed to Menarini Group, and RAD011, a synthetic cannabidiol oral solution that is being developed for the treatment of Prader-Willi syndrome (PWS).
More about the company
  1. Stock
  2. Equities
  3. Stock Radius Health, Inc. - Nasdaq
  4. News Radius Health, Inc.
  5. Radius Health : SVB Leerink Adjusts Radius Health's Price Target to $29 from $26, Keeps Market Perform Rating